Pharmaceutical Excipients Market By Type (Organic Excipients, Inorganic Excipients), By Function (Fillers & Diluents, Binders, Disintegrants, Lubricants, Preservatives), By Dosage Form (Oral Formulations, Parenteral Formulations, Topical Formulations), and By Region; Global Insights & Forecast (2023 – 2030)

As per Intent Market Research, the Pharmaceutical Excipients Market was valued at USD 10.8 Billion in 2024-e and will surpass USD 15.9 Billion by 2030; growing at a CAGR of 6.6% during 2025-2030.

The pharmaceutical excipients market is crucial for the formulation of drugs, assisting in the delivery of active pharmaceutical ingredients (APIs) with desired characteristics such as stability, solubility, and bioavailability. Excipients are added to drug formulations to improve their performance, safety, and patient compliance. The market is experiencing significant growth due to the increasing demand for novel drug formulations, biologics, and the rising consumption of generic drugs. The market is segmented by type, function, dosage form, and region, each catering to different drug delivery needs. The growing trend of personalized medicine and innovations in drug delivery systems are expected to continue to shape the landscape, making pharmaceutical excipients an integral part of the pharmaceutical industry.

Organic Excipients Segment is Largest Owing to Their Role in Drug Bioavailability

Organic excipients form the largest segment in the pharmaceutical excipients market, driven by their essential role in the bioavailability and stability of oral and parenteral drug formulations. These excipients are derived from natural sources such as cellulose, starch, and gums, and are used extensively in tablets, capsules, and liquid formulations. Their ability to enhance the solubility of poorly soluble drugs and improve the stability of active ingredients makes them indispensable in modern pharmaceutical formulations. Organic excipients, such as fillers, binders, and disintegrants, play key roles in drug delivery systems, ensuring that patients receive the most effective therapeutic doses.

As drug formulations become more complex and tailored to individual needs, the demand for organic excipients is expected to rise further. Organic excipients, such as hydroxypropyl methylcellulose (HPMC) and microcrystalline cellulose (MCC), are particularly important in controlled-release formulations, contributing to more consistent therapeutic effects, improving patient compliance, and reducing side effects. Their versatility and effectiveness across different drug types make organic excipients the largest segment in the pharmaceutical excipients market.

Fillers & Diluents Segment is Fastest Growing Owing to the Demand for Oral Formulations

Fillers and diluents are the fastest-growing subsegment within the pharmaceutical excipients market, primarily due to their critical role in the development of oral formulations. As the global demand for oral drugs, particularly tablets and capsules, continues to expand, so does the demand for fillers and diluents. These excipients are used to add bulk to formulations, making them easier to handle, and ensuring that the active ingredients are delivered in the correct dose. The growing preference for oral drug delivery due to its convenience and cost-effectiveness is expected to continue driving the demand for fillers and diluents.

Fillers such as microcrystalline cellulose (MCC), calcium phosphate, and starch derivatives are widely used in the production of tablets and capsules. These excipients not only help in achieving the desired volume but also contribute to the stability of the formulation and improve tablet hardness and disintegration. The growing prevalence of chronic diseases and the increasing adoption of generic drugs are expected to further fuel the demand for fillers and diluents, making this subsegment one of the fastest-growing in the pharmaceutical excipients market.

Oral Formulations Segment is Largest Owing to its Widespread Usage in Drug Delivery

The oral formulations segment holds the largest share in the pharmaceutical excipients market, driven by the widespread use of oral drugs globally. Oral drug delivery remains the most preferred method due to its ease of administration, patient convenience, and cost-effectiveness. The market for oral formulations is expanding rapidly, particularly in the context of generics and over-the-counter (OTC) medications. Excipients used in oral formulations, such as binders, disintegrants, and fillers, are crucial in the formulation of tablets, capsules, and liquid oral drugs, ensuring that the active ingredients are delivered effectively to the patient.

The growing demand for oral drugs, especially in the treatment of chronic diseases such as diabetes, cardiovascular diseases, and oncology, is expected to continue driving the market for excipients used in oral formulations. Furthermore, the development of novel oral delivery systems, such as controlled-release and extended-release tablets, is expected to contribute to the sustained growth of this segment. As a result, the oral formulations segment remains the largest in the pharmaceutical excipients market, with a promising outlook for the future.

Asia-Pacific Region is Fastest Growing Due to Increasing Pharmaceutical Production

The Asia-Pacific region is the fastest-growing region in the pharmaceutical excipients market. This growth is fueled by the increasing pharmaceutical production capacity in countries like China and India, which are emerging as global hubs for drug manufacturing. The growing healthcare infrastructure, rising investments in the pharmaceutical industry, and increasing demand for generics in the region are contributing to the rapid expansion of the market. Additionally, the rise in chronic disease prevalence and the growing adoption of personalized medicine in Asia-Pacific are expected to further propel the demand for pharmaceutical excipients.

India, in particular, has become a key player in the global pharmaceutical industry, accounting for a significant share of the global market for generic drugs. This has led to an increased need for pharmaceutical excipients that ensure drug stability, solubility, and bioavailability. The region's rapid development in pharmaceutical production and drug exports makes Asia-Pacific a critical growth area for the excipients market.

Leading Companies and Competitive Landscape

Key players in the pharmaceutical excipients market include BASF SE, Evonik Industries AG, Dow Chemical Company, Ashland Global Holdings Inc., Colorcon, Inc., and Lubrizol Corporation. These companies have established themselves as leaders in the development and supply of excipients, driving innovation in drug delivery systems and expanding their product portfolios. To maintain a competitive edge, these companies are focusing on research and development to create new excipients that cater to the growing demand for biologics, personalized medicine, and complex drug formulations.

The competitive landscape is characterized by collaborations, acquisitions, and mergers aimed at strengthening product offerings and expanding market share. For instance, BASF's acquisition of the functional excipients business from the Swiss chemical company, Lonza, has enhanced its position in the pharmaceutical excipients market. Similarly, companies are increasingly investing in sustainable and cost-effective excipient solutions, focusing on meeting the growing demand for high-quality drug formulations. The market is expected to remain highly competitive, with leading companies continuously innovating to meet the evolving needs of the pharmaceutical industry.

Recent Developments:

• BASF announced the launch of a new excipient for oral solid dosage forms, enhancing the bioavailability of poorly soluble drugs.
• Ashland Global Holdings expanded its portfolio of excipients with new products for topical drug formulations, improving skin penetration.
• Evonik Industries unveiled a new line of excipients tailored for controlled release drug formulations, increasing patient compliance.
• Dow Chemical introduced a new excipient for injectable formulations, improving stability and reducing the risk of aggregation in biologics.
• Colorcon acquired a leading supplier of excipients used in controlled-release formulations, strengthening its position in the drug delivery market.

List of Leading Companies:

• BASF SE
• Evonik Industries AG
• Dow Chemical Company
• Ashland Global Holdings Inc.
• Colorcon, Inc.
• Lubrizol Corporation
• FMC Corporation
• Sigma-Aldrich Co. LLC
• The Medline Industries Inc.
• Innophos, Inc.
• Wacker Chemie AG
• Croda International Plc
• Hunan Er-Kang Pharmaceutical Co., Ltd.
• Jiangsu Hualun Pharmaceutical Co., Ltd.
• Zhejiang Medicine Co., Ltd.

Report Scope: